GlassScriptPhysician profile
Crystal Lynn Stone
NPI 1518328624
$6,788.62
in general payments reported to CMS, 2019-2025
41 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $286 · 2022: $1,098 · 2023: $1,616 · 2024: $1,515 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,295 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,294.66 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,185.23 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $723.91 | 2022-2025 | Abilify Maintena, Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $605.35 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $539.21 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $490.03 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $397.33 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $279.37 | 2022-2024 | Ingrezza, Ongentys |
| Axsome Therapeutics, INC. | $279.04 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $254.98 | 2021-2023 | Farxiga, Breztri |
| E.R. Squibb & Sons, L.L.C. | $235.59 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $185.12 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Lundbeck LLC | $159.84 | 2023-2025 | Rexulti |
| Alkermes, INC. | $139.68 | 2024-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $130.16 | 2021-2025 | Trintellix |
| Acadia Pharmaceuticals INC | $99.14 | 2022-2024 | Nuplazid |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $97.09 | 2022-2024 | Adzenys Xr-Odt |
| Biohaven Pharmaceutical Holding Company LTD. | $91.81 | 2022 | |
| Astellas Pharma US INC | $88.60 | 2022-2023 | Myrbetriq |
| Lilly USA, LLC | $87.03 | 2022-2025 | Zepbound, Kisunla, Mounjaro |
| Abbott Laboratories | $59.44 | 2021-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.91 | 2022-2025 | Xifaxan |
| Alpha Cognition USA, INC. | $53.24 | 2025 | Zunveyl |
| Indivior INC. | $49.34 | 2022-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $46.45 | 2025 | Qelbree |
| Ucb, INC. | $45.54 | 2021 | |
| Novo Nordisk INC | $42.23 | 2022-2023 | Ozempic, Rybelsus |
| Sunovion Pharmaceuticals INC. | $39.07 | 2022 | |
| Pfizer INC. | $38.56 | 2021 | |
| Avanir Pharmaceuticals, INC. | $34.22 | 2021-2022 | |
| Kyowa Kirin, INC. | $30.72 | 2022 | |
| Amgen INC. | $29.66 | 2023 | Repatha, Otezla |
| Luye Pharma (USA) LTD. | $28.83 | 2025 | Erzofri Extended-Release |
| Avadel Cns Pharmaceuticals, LLC | $24.86 | 2025 | Lumryz |
| Bioxcel Therapeutics, INC. | $24.03 | 2025 | Igalmi |
| Tactile Systems Technology INC | $20.99 | 2023 | Entre Plus, Flexitouch Plus |
| Sage Therapeutics, LLC | $20.09 | 2024 | |
| Corium, LLC | $15.90 | 2023 | Adlarity |
| Acorda Therapeutics, INC | $15.62 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.61 | 2022 | |
| Acerus Pharmaceuticals Corporation | $14.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.